Table 1 Human studies of the gut virome in metabolic disorders
From: Characterization of the human gut virome in metabolic and autoimmune diseases
Disease | Study population | References |
|---|---|---|
Obesity | obese subjects (n= 128) and lean controls (n= 101) in China | [39] |
Obesity + MetS | obese (n= 10), obese with MetS (n= 8) and normal weight children (n= 10) in Mexico | [40] |
Obesity + MetS | obese subjects with MetS (n= 9: self-stool transplant, n= 3; healthy-donor-stool transplant recipients, n= 6) in the Netherlands | [41] |
NAFLD | NAFLD patients (n= 73: NAS of 0–4, n= 29; NAS of 5–8 or liver cirrhosis, n= 44) and controls without liver disease (n= 9) in Germany | [42] |
T2DM | T2DM patients (n= 71) and nondiabetic controls (n= 74) in China | [43] |
T2DM + Obesity | T2DM patients with obesity (n= 74) and lean controls (n= 101) in China | [39] |
T2DM | T2DM patients (n= 17) and nondiabetic controls (n= 29) in China | [44] |
CVD | coronary heart disease inpatients (n= 37) and healthy residents without a history of CVD (n= 6) in China | [45] |
CVD | atherosclerotic CVD patients (n= 218) and healthy controls (n= 187) in China | [46] |
Hypertension | hypertension patients (n= 99), prehypertension (n= 56) and healthy controls (n= 41) in China | [47] |